Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, review the impact of real-world analysis and how they may shape guidelines and clinical approaches with respect to the use of CAR T-cell therapy in LBCL.In particular, they note how continued research bolsters the safety profile of these agents.
Caron A. Jacobson, MD, discusses the significance of a real-world follow-up analysis of liso-cel in which safety and efficacy findings in patients with comorbidities and others who were not eligible for clinical trials were consistent with those studies.
In good news, CAR-T cell therapy, an indigenous cancer treatment recently licenced by India's drug regulator, has resulted in the cure of a patient with cancer.